CFO Jon Moeller drives home that P&G is "operating in a more volatile environment than we ever have" as it continues shedding slow-growth brands and that the firm gives "particular priority" to spurring growth in categories other than health care.
Procter & Gamble Co. pulls no punches describing market conditions and the difficulty of shedding underperforming brands, but is more subtle on its priority for growing its consumer health products business.
While the dip in net sales across all the firm's product categories in its latest quarter was smallest in health...
FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.
At this year’s DIA China meeting, the national regulator updated its policy focus areas for this year, including clinical trial data protection and pilot projects to shorten IND approval times.
Legislation prohibiting work with certain Chinese biopharma firms will be reintroduced soon, Democratic Sen. Gary Peters said. And it will not be the only bill tied to international biotech competition and security concerns that will be considered.
As the US FDA expands unannounced foreign inspections building on pilots in India and China, experts expect higher scrutiny of overseas sites and perhaps even an industry shakeout in the longer term, though staffing and enforcement challenges could slow things down.
